ABBVIE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25 CAD | +1.46% |
|
+0.36% | +10.28% |
| 06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
| 06-28 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
